In recent trading session, Adma Biologics Inc (NASDAQ:ADMA) saw 0.68 million shares changing hands at last check today with its beta currently measuring 0.62. Company’s recent per share price level of $16.60 trading at $0.16 or 0.95% at last check today assigns it a market valuation of $3.87B. That most recent trading price of ADMA’s stock is at a discount of -27.29% from its 52-week high price of $21.13 and is indicating a premium of 81.57% from its 52-week low price of $3.06. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 6.05 million shares which gives us an average trading volume of 5.25 million if we extend that period to 3-months.
For Adma Biologics Inc (ADMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.13 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ:ADMA) trade information
Upright in the green today for gaining 0.95%, in the last five days ADMA remained trading in the red while hitting it’s week-highest on Friday, 10/11/24 when the stock touched $16.60 price level, adding 4.76% to its value on the day. Adma Biologics Inc’s shares saw a change of 267.19% in year-to-date performance and have moved -2.43% in past 5-day. Adma Biologics Inc (NASDAQ:ADMA) showed a performance of -14.10% in past 30-days. Number of shares sold short was 17.08 million shares which calculate 2.38 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a fall of -3.75% to its recent value today. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would jump 15.66% in reaching the projected high whereas dropping to the targeted low would mean a gain of 15.66% for stock’s current value.
Adma Biologics Inc (ADMA) estimates and forecasts
This year revenue growth is estimated to rise 57.10% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 105.85M for the same. And 4 analysts are in estimates of company making revenue of 110.7M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 38.68% during past 5 years.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders are in possession of 2.58% of company’s total shares while institution are holding 80.70 percent of that, with stock having share float percentage of 82.84%. Investors also watch the number of corporate investors in a company very closely, which is 80.70% institutions for Adma Biologics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ADMA for having 18.64 million shares of worth $208.45 million. And as of 2024-06-30, it was holding 8.1462 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 14.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3426 of outstanding shares, having a total worth of $162.3 million.
